CN113278064B - 一种用于胚毒类抗原净化处理的方法及其应用 - Google Patents
一种用于胚毒类抗原净化处理的方法及其应用 Download PDFInfo
- Publication number
- CN113278064B CN113278064B CN202110817861.9A CN202110817861A CN113278064B CN 113278064 B CN113278064 B CN 113278064B CN 202110817861 A CN202110817861 A CN 202110817861A CN 113278064 B CN113278064 B CN 113278064B
- Authority
- CN
- China
- Prior art keywords
- antigen
- supernatant
- embryo
- embryotoxic
- antigens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 105
- 102000036639 antigens Human genes 0.000 title claims abstract description 105
- 108091007433 antigens Proteins 0.000 title claims abstract description 105
- 238000000034 method Methods 0.000 title claims abstract description 58
- 231100000758 embryotoxin Toxicity 0.000 title claims description 13
- 239000006228 supernatant Substances 0.000 claims abstract description 40
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 38
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 28
- 239000001110 calcium chloride Substances 0.000 claims abstract description 28
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 28
- 239000012530 fluid Substances 0.000 claims abstract description 24
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims abstract description 21
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims abstract description 21
- 231100000351 embryotoxic Toxicity 0.000 claims abstract description 16
- 230000001779 embryotoxic effect Effects 0.000 claims abstract description 16
- 239000000706 filtrate Substances 0.000 claims abstract description 15
- 150000002632 lipids Chemical class 0.000 claims abstract description 13
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 241000700605 Viruses Species 0.000 claims abstract description 11
- 229960002446 octanoic acid Drugs 0.000 claims abstract description 11
- 238000000227 grinding Methods 0.000 claims abstract description 8
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims abstract description 6
- 238000001914 filtration Methods 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 31
- 238000000746 purification Methods 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 21
- 241000271566 Aves Species 0.000 claims description 17
- 241000272525 Anas platyrhynchos Species 0.000 claims description 15
- 210000002969 egg yolk Anatomy 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 241000272814 Anser sp. Species 0.000 claims description 11
- 206010019799 Hepatitis viral Diseases 0.000 claims description 9
- 238000005119 centrifugation Methods 0.000 claims description 9
- 201000001862 viral hepatitis Diseases 0.000 claims description 9
- 206010035148 Plague Diseases 0.000 claims description 8
- 241000607479 Yersinia pestis Species 0.000 claims description 8
- 210000002257 embryonic structure Anatomy 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 241000167854 Bourreria succulenta Species 0.000 claims description 4
- 235000019693 cherries Nutrition 0.000 claims description 4
- 238000005202 decontamination Methods 0.000 claims description 4
- 241000287828 Gallus gallus Species 0.000 claims description 3
- 230000003588 decontaminative effect Effects 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 3
- 238000010257 thawing Methods 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000003306 harvesting Methods 0.000 claims description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 229960005486 vaccine Drugs 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 210000003837 chick embryo Anatomy 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 210000001643 allantois Anatomy 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 241000272808 Anser Species 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110817861.9A CN113278064B (zh) | 2021-07-20 | 2021-07-20 | 一种用于胚毒类抗原净化处理的方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110817861.9A CN113278064B (zh) | 2021-07-20 | 2021-07-20 | 一种用于胚毒类抗原净化处理的方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113278064A CN113278064A (zh) | 2021-08-20 |
CN113278064B true CN113278064B (zh) | 2021-11-02 |
Family
ID=77286856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110817861.9A Active CN113278064B (zh) | 2021-07-20 | 2021-07-20 | 一种用于胚毒类抗原净化处理的方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113278064B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103172732A (zh) * | 2011-12-20 | 2013-06-26 | 普莱柯生物工程股份有限公司 | 一种抗小鹅瘟蛋黄抗体及其制备方法 |
CN104530232A (zh) * | 2014-12-23 | 2015-04-22 | 山东信得科技股份有限公司 | 鸭病毒性肝炎精制蛋黄抗体的制备方法 |
CN106075427A (zh) * | 2016-06-30 | 2016-11-09 | 武汉中博生物股份有限公司 | 1型禽腺病毒疫苗、蛋黄抗体的制备方法 |
CN107325178A (zh) * | 2017-06-29 | 2017-11-07 | 佛山市南海区普罗圣塔生物科技有限公司 | 一种抗人巨细胞病毒卵黄抗体及其制备方法和应用 |
CN110590944A (zh) * | 2019-08-29 | 2019-12-20 | 广东渔跃生物技术有限公司 | 一种鸭坦布苏病毒卵黄抗体的制备方法 |
CN111303252A (zh) * | 2020-02-17 | 2020-06-19 | 青岛易邦生物工程有限公司 | 一种规模化生产胚毒类抗原的净化方法 |
CN113072641A (zh) * | 2021-06-04 | 2021-07-06 | 山东信得科技股份有限公司 | 一种卵黄抗体的制备方法及卵黄抗体 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR004464A1 (es) * | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
WO2005051313A2 (en) * | 2003-11-19 | 2005-06-09 | Chiron Corporation | Methods and reagents for treating, preventing and diagnosing bunyavirus infection |
FR2957933B1 (fr) * | 2010-03-24 | 2012-04-27 | Seppic Sa | Vaccin vivant pour maladies aviaires |
BR112014001052A2 (pt) * | 2011-07-22 | 2017-02-21 | Glaxosmithkline Biologicals Sa | método para reduzir a agregação de uma proteína, uso de uma composição polianiônica, composição, e, método e processo para a produção de uma composição |
US20140234337A1 (en) * | 2011-08-19 | 2014-08-21 | Immortal Spirit Limited | Antibody and antibody-containing composition |
-
2021
- 2021-07-20 CN CN202110817861.9A patent/CN113278064B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103172732A (zh) * | 2011-12-20 | 2013-06-26 | 普莱柯生物工程股份有限公司 | 一种抗小鹅瘟蛋黄抗体及其制备方法 |
CN104530232A (zh) * | 2014-12-23 | 2015-04-22 | 山东信得科技股份有限公司 | 鸭病毒性肝炎精制蛋黄抗体的制备方法 |
CN106075427A (zh) * | 2016-06-30 | 2016-11-09 | 武汉中博生物股份有限公司 | 1型禽腺病毒疫苗、蛋黄抗体的制备方法 |
CN107325178A (zh) * | 2017-06-29 | 2017-11-07 | 佛山市南海区普罗圣塔生物科技有限公司 | 一种抗人巨细胞病毒卵黄抗体及其制备方法和应用 |
CN110590944A (zh) * | 2019-08-29 | 2019-12-20 | 广东渔跃生物技术有限公司 | 一种鸭坦布苏病毒卵黄抗体的制备方法 |
CN111303252A (zh) * | 2020-02-17 | 2020-06-19 | 青岛易邦生物工程有限公司 | 一种规模化生产胚毒类抗原的净化方法 |
CN113072641A (zh) * | 2021-06-04 | 2021-07-06 | 山东信得科技股份有限公司 | 一种卵黄抗体的制备方法及卵黄抗体 |
Non-Patent Citations (5)
Title |
---|
Clarification of vaccines: An overview of filter based technology trends and best practices;Lise Besnard等;《Biotechnology Advances》;20151202;全文 * |
低分子量聚丙烯酸(钠)的研究及应用进展;程终发等;《2013中国水处理技术研讨会暨第33届年会论文集》;20131031;第17页概述 * |
抗禽传染性法氏囊病毒卵黄抗体的研制及应用;张伦;《中国优秀博硕士学位论文全文数据库(硕士)农业科技辑》;20110715;全文 * |
泊洛沙姆―辛酸法对鸡卵黄脱脂条件的研究;张伦等;《中国动物检疫》;20110301(第03期);全文 * |
聚丙烯酸钠絮凝剂文献综述;闂傝尪濮抽拃浠嬫穿;《百度文库》;20150430;全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN113278064A (zh) | 2021-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102827275B (zh) | 鸭病毒性肝炎二价精制卵黄抗体的制备方法 | |
CN103172732B (zh) | 一种抗小鹅瘟蛋黄抗体及其制备方法 | |
CN111000993B (zh) | 一种鸭病毒性肝炎、鸭呼肠孤病毒病二联灭活疫苗及其制备方法 | |
CN103833848B (zh) | 一种用于预防治疗番鸭细小病毒病的卵黄抗体 | |
CN102716483A (zh) | 一种鸭瘟卵黄抗体冻干粉及其制备方法 | |
CN101704890B (zh) | 一种鸭肝炎抗体的制备方法 | |
CN105504050A (zh) | 一种抗安卡拉病毒鸡卵黄抗体的制备方法 | |
CN108912227B (zh) | 一种抗鸭呼肠孤病毒的卵黄抗体及其制备方法和应用 | |
CN105664150A (zh) | 一种鸡新城疫病毒、禽流感病毒和禽腺病毒三联灭活疫苗 | |
CN105582533A (zh) | 一种禽流感病毒、禽腺病毒二联灭活疫苗 | |
CN113493507B (zh) | 新型鸭呼肠孤病毒卵黄抗体及其制备方法和应用 | |
CN104548088A (zh) | 一种鸡新城疫病毒La Sota株和鸡传染性支气管炎病毒N-S多表位蛋白二联疫苗制备方法 | |
CN108676092B (zh) | 一种防治新型鸭呼肠孤病毒的卵黄抗体及其制备方法 | |
CN113278064B (zh) | 一种用于胚毒类抗原净化处理的方法及其应用 | |
CN101704889B (zh) | 一种鸡法氏囊抗体的制备方法 | |
CN106563125B (zh) | 鸭甲肝病毒ⅲ型复合物活疫苗及其制备方法 | |
CN104888213A (zh) | 一种猪瘟脾淋源复合活疫苗的制备方法 | |
CN105535958A (zh) | 一种鸡新城疫病毒、传染性支气管炎、禽腺病毒三联灭活疫苗 | |
CN109762062B (zh) | 一种鹅痛风病卵黄抗体的制备方法 | |
CN111349619A (zh) | 一种鸭圆环病毒组织灭活疫苗及其卵黄抗体的制备方法 | |
CN103122336B (zh) | 一种鹅细小病毒h株及其在小鹅瘟防治中的应用 | |
CN104984337A (zh) | 一种鸡新城疫、禽流感抗原抗体复合物灭活疫苗及其制备方法 | |
CN112608382B (zh) | 鸭呼肠孤病毒病、鸭病毒性肝炎二联卵黄抗体及其制备方法 | |
US3470294A (en) | Vaccine for immunization of dogs and foxes against distemper,hepatitis contagiosa and leptospirosis and process for preparing it | |
CN111632139A (zh) | 一种鸡腺病毒卵黄抗体全蛋喷干粉的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A method for purification of embryo virus antigen and its application Effective date of registration: 20211222 Granted publication date: 20211102 Pledgee: Shandong Zhucheng rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG SINDER TECHNOLOGY Co.,Ltd. Registration number: Y2021980015708 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221223 Granted publication date: 20211102 Pledgee: Shandong Zhucheng rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG SINDER TECHNOLOGY Co.,Ltd. Registration number: Y2021980015708 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Method and Its Application for Purification of Embryotoxin Antigens Effective date of registration: 20230608 Granted publication date: 20211102 Pledgee: Shandong Zhucheng rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG SINDER TECHNOLOGY Co.,Ltd. Registration number: Y2023980043376 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20211102 Pledgee: Shandong Zhucheng rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG SINDER TECHNOLOGY Co.,Ltd. Registration number: Y2023980043376 |